Dedicated CKD‐specific trials—DAPA‐CKD, CREDENCE, and EMPA‐KIDNEY, have further confirmed that SGLT‐2 inhibitors significantly reduce the risk of GFR decline, end‐stage renal disease, or death, even in patients without diabetes (Table 1) [16, 17, 23]. This evidence concerns the gene SLC5A2 and diabetes mellitus.